Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Post-marketing safety and effectiveness of sofosbuvir-based regimens in chronic HCV infection in China
CTR20191097Phase 4Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of sofosbuvir, ledipasvir, velpatasvir, sofosbuvir + velpatasvir + voxilaprevir in hepatitis C virus infection, sponsored by Gilead Sciences. Started Jun 2019; status: completed.
02
Drugs
sofosbuvirledipasvirvelpatasvirsofosbuvir + velpatasvir + voxilaprevir
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on CTR20191097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191097.